摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

10-chloro-9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide | 32186-92-8

中文名称
——
中文别名
——
英文名称
10-chloro-9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide
英文别名
6-Chlorobenzo[c][2,1]benzoxaphosphinine 6-oxide
10-chloro-9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide化学式
CAS
32186-92-8
化学式
C12H8ClO2P
mdl
——
分子量
250.621
InChiKey
GCDRIRYINCSSIW-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    16
  • 可旋转键数:
    0
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量
    • 1
    • 2
    • 3
    • 4
    • 5

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Chernyshev,E.A. et al., Journal of general chemistry of the USSR, 1971, vol. 41, p. 2214 - 2216
    摘要:
    DOI:
  • 作为产物:
    参考文献:
    名称:
    Method for preparing a biphenylphosphonate compound
    摘要:
    制备以下式(I)的二苯基膦酸酯化合物的方法:其中n为2或3;Ar为C6-C16芳香基团;包括以下步骤:(a)在锌氯化物催化剂存在下,将邻苯酚与三氯化磷反应,形成以下式(II)的6-氯-6H-二苯[c,e][1,2]氧磷杂环戊烷;(b)将式(III)的多羟基苯化合物(HO)n—Ar(III)(其中n和Ar的定义与上述相同)与式(II)的化合物反应,形成以下式(IV)的化合物;其中n和Ar的定义与上述相同;(c)在水和臭氧存在下氧化式(IV)的化合物,形成式(I)的化合物。
    公开号:
    US20050101793A1
点击查看最新优质反应信息

文献信息

  • Process for preparing 10-chloro-9, 10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide compound
    申请人:UFC Corporation
    公开号:US08703986B1
    公开(公告)日:2014-04-22
    Provided is a process for preparing 10-chloro-9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide (DOPO-C) compound, the process having steps of: reacting a liquid chlorinating agent and 9,10-dihydro-10-hydroxy-9-oxa 10-phosphaphenanthrene 10-oxide compound represented by formula (B) to form a mixture, the mixture comprises DOPO-C compound represented by formula (A) and an unreacted liquid chlorinating agent, separating the DOPO-C compound and the unreacted liquid chlorinating agent from the mixture to obtain the DOPO-C compound; wherein X1, X2, and X3 are each independently selected from the group consisting of hydrogen atom, hydroxyl group, cyano group, sulfonic acid group, sulfonate ester group represented by —SO3R1, halogen atom, alkoxy group represented by —OR2, acyclic hydrocarbon group having 1 to 8 carbon atoms, cyclic alkyl group having 3 to 8 carbon atoms, aryl group, heteroaryl group, and arylalkyl group, wherein R1 and R2 are each an acyclic hydrocarbon group having 1 to 8 carbon atoms.
    提供了一种制备10-氯-9,10-二氢-9-氧-10-磷代菲-10-氧化物(DOPO-C)化合物的过程,该过程包括以下步骤:将液体氯化剂与由式(B)表示的9,10-二氢-10-羟基-9-氧-10-磷代菲-10-氧化物化合物反应,形成混合物,该混合物包含由式(A)表示的DOPO-C化合物和未反应的液体氯化剂,将DOPO-C化合物和未反应的液体氯化剂从混合物中分离出来,以获得DOPO-C化合物;其中X1、X2和X3分别独立地选自氢原子、羟基、氰基、磺酸基、由—SO3R1表示的磺酸酯基、卤素原子、由—OR2表示的烷氧基、具有1至8个碳原子的非环烃基、具有3至8个碳原子的环烷基、芳基、杂环芳基和芳基烷基的群,其中R1和R2分别是具有1至8个碳原子的非环烃基。
  • Synthesis of Trispirocyclotriphosphazenes with Oxaphosphorine Rings and Their Crystal and Molecular Structures
    作者:Yuji Tada、Atsushi Sunada、Riki Watanabe、Makoto Kanazawa、Keiichiro Utsumi
    DOI:10.1021/acs.inorgchem.1c00054
    日期:2021.4.5
    were characterized by 1H, 13C1H}, and 31P1H} nuclear magnetic resonance spectroscopy and time-of-flight mass spectrometry and shown to consist of cis–trans isomers. Moreover, the crystal and molecular structures of the DOP-PZs were determined by X-ray diffraction; cis- and trans-DOP-PZs (C36H24N3O3P3, M = 639.49 g/mol) were refined to final R1 values of 0.0260 and 0.0463, respectively, with the SHELXL
    通过氨与10-氯-9,10-二氢-9-氧杂-10-膦菲10氧化物从9衍生而来的磷酰胺的Appel反应成功地合成了具有氧杂磷环(DOP-PZs)的新型三螺环三磷腈(DOP-PZs)。 ,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide,通常缩写为DOPO。所得DOP-PZs的特征在于1 H,13 C 1 H}和31 P 1 H}核磁共振波谱和飞行时间质谱,并显示由顺-反异构体组成。此外,通过X射线衍射确定了DOP-PZ的晶体和分子结构。顺式和反式使用最小二乘最小化的SHELXL精制软件包,将-DOP-PZs(C 36 H 24 N 3 O 3 P 3,M = 639.49 g / mol)精制为最终R 1值0.0260和0.0463。的晶体顺-DOP-PZ是在空间群三角- [R 3 Ç和下面的晶胞常数:一个= 19.5984(5),C ^
  • Phosphonamidate Compounds for Butyrylcholinesterase Selective Inhibitors
    作者:Jintaek Oh、Jung‐Youl Park、Kyoung Chan Park、Ji Hyun Hwang、Jeong Ho Park
    DOI:10.1002/bkcs.12126
    日期:2020.12
    To find a new type of cholinergic drug, phosphonamidate compounds 18–32 were synthesized using a click reaction between propargylated‐9,10Dihydro‐9‐oxa‐10‐phosphaphenanthrene‐10‐oxide (DOPO, 2) and substituted benzyl azide. Their inhibitory activity against butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE) was evaluated. Compound 31 was the most active of the 15 compounds (IC50 = 3.14 ± 0
    为了找到一种新型的胆碱能药物,使用炔丙基化的9,10-二氢-9-氧杂-10-磷杂菲-10-氧化物(DOPO,2)和取代的叠氮化苄之间的点击反应合成了膦酰胺化合物18–32。评价了它们对丁酰胆碱酯酶(BuChE)和乙酰胆碱酯酶(AChE)的抑制活性。化合物31是15种化合物中活性最高的(马类BuChE的IC 50 = 3.14±0.02μM),其IC 50值略低于加兰他敏的IC 50值(马类BuChE的IC 50 = 9.4±2.50)。
  • Industrial Upscaling of DOPO-Based Phosphonamidates and Phosphonates Derivatives Using Cl<sub>2</sub> Gas as a Chlorinating Agent
    作者:Khalifah A. Salmeia、Georg Baumgartner、Milijana Jovic、Angelo Gössi、Wolfgang Riedl、Thomas Zich、Sabyasachi Gaan
    DOI:10.1021/acs.oprd.8b00295
    日期:2018.11.16
    and used for this synthesis of DOPO-based phosphonamidates and phosphonates in relatively high yield by reaction with the corresponding amines and alcohols, respectively. The experimental results show that the chlorination reaction occurs in equimolar ratios of Cl2 gas to DOPO compound. Subsequently, the procedure developed in laboratory scale was industrially applied for synthesis of the 6,6′-(ethane-1
    在本文中,我们报告了通过Cl 2气体对9,10-dihydro-9-oxa-10-phosphaphenanthren-10-oxide(DOPO)进行有效而简单的氯化,从而合成了膦酰胺和膦酸酯衍生物的工业合成方法。合成中的关键步骤是通过使Cl 2流动将P–H键转变为DOPO的P–Cl。将其通入DOPO的二氯甲烷溶液中,得到关键的中间体9,10-二氢-9-氧杂-10-磷菲基-10-氯化物(DOPO-Cl)化合物,该化合物在工业上无法获得。分离,表征DOPO-Cl,并通过分别与相应的胺和醇反应,以相对高的产率用于基于DOPO的膦酸酯和膦酸酯的合成。实验结果表明,氯化反应以Cl 2气体与DOPO化合物的等摩尔比进行。随后,将实验室规模开发的方法工业化用于合成6,6'-(乙烷-1,2-二基双(氮杂二基))双(二苯并[ c,e] [1,2]氧杂膦-6-氧化物)(EDA-DOPO)化合物和6-((1-氧化-2
  • [EN] A PROCESS FOR PREPARATION OF DOPO DERIVATIVES<br/>[FR] PROCÉDÉ DE PRÉPARATION DE DÉRIVÉS DOPO
    申请人:METADYNEA AUSTRIA GMBH
    公开号:WO2019002201A1
    公开(公告)日:2019-01-03
    The present invention relates to a process for the preparation of a DOPO derivative DOPO-X comprising a 9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide DOPO moiety and a derivative group X according to formula 1, the process comprising the preparation of a DOPO derivative wherein X = CI comprising the steps; a) providing a solution of DOPO in a solvent, b) introducing chlorine into the DOPO solution whilst maintaining a maximum reaction temperature below 20°C forming DOPO-CI, c) optionally removing volatiles and/or crystallising DOPO-CI, d) optionally further derivatization reaction steps. The invention further relates to DOPO-CI obtainable by the process having high purity, to the use thereof in a process for preparation of further DOPO-derivatives and the high purity products obtained, in particular DOPO-EDA, DOPO-ETA or DOPO-PEPA and the use thereof in polymer composition as flame retardant.
    本发明涉及一种制备DOPO衍生物DOPO-X的方法,其中包括9,10-二氢-9-氧-10-磷杂蒽-10-氧化物DOPO基团和根据式1的衍生基团X的DOPO衍生物的制备过程,该过程包括制备一个DOPO衍生物,其中X = CI,包括以下步骤:a)提供DOPO在溶剂中的溶液,b)在保持最大反应温度低于20°C的情况下向DOPO溶液中引入氯,形成DOPO-CI,c)可选择性地去除挥发物和/或结晶DOPO-CI,d)可选择性地进一步进行衍生反应步骤。该发明还涉及通过该方法获得的高纯度DOPO-CI,以及其在制备进一步的DOPO衍生物和获得的高纯度产品中的用途,特别是DOPO-EDA、DOPO-ETA或DOPO-PEPA以及其在聚合物组合物中作为阻燃剂的用途。
查看更多

同类化合物

2,9-二(2-苯乙基)蒽并[2,1,9-DEF:6,5,10-D’E’F’]二异喹啉-1,3,8,10(2H,9H)-四酮 (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-盐酸沙丁胺醇 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-3,3''-双([[1,1''-联苯]-4-基)-[1,1''-联萘]-2,2''-二醇 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4S,5R)-3,3a,8,8a-四氢茚并[1,2-d]-1,2,3-氧杂噻唑-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aS,8aR)-2-(吡啶-2-基)-8,8a-二氢-3aH-茚并[1,2-d]恶唑 (3aS,3''aS,8aR,8''aR)-2,2''-环戊二烯双[3a,8a-二氢-8H-茚并[1,2-d]恶唑] (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (3S,3aR)-2-(3-氯-4-氰基苯基)-3-环戊基-3,3a,4,5-四氢-2H-苯并[g]吲唑-7-羧酸 (3R,3’’R,4S,4’’S,11bS,11’’bS)-(+)-4,4’’-二叔丁基-4,4’’,5,5’’-四氢-3,3’’-联-3H-二萘酚[2,1-c:1’’,2’’-e]膦(S)-BINAPINE (3-三苯基甲氨基甲基)吡啶 (3-[(E)-1-氰基-2-乙氧基-2-hydroxyethenyl]-1-氧代-1H-茚-2-甲酰胺) (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,4S)-Fmoc-4-三氟甲基吡咯烷-2-羧酸 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,3R)-3-(叔丁基)-2-(二叔丁基膦基)-4-甲氧基-2,3-二氢苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S,2''S,3S,3''S)-3,3''-二叔丁基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2R,2''R,3R,3''R)-3,3''-二叔丁基-4,4''-二甲氧基-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2-硝基苯基)磷酸三酰胺 (2-氯-6-羟基苯基)硼酸 (2-氟-3-异丙氧基苯基)三氟硼酸钾 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1α,1'R,4β)-4-甲氧基-5''-甲基-6'-[5-(1-丙炔基-1)-3-吡啶基]双螺[环己烷-1,2'-[2H]indene (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1R,1′R,2S,2′S)-2,2′-二叔丁基-2,3,2′,3′-四氢-1H,1′H-(1,1′)二异磷哚